Compare DSGX & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSGX | CRL |
|---|---|---|
| Founded | 1981 | 1947 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 8.0B |
| IPO Year | 1999 | 2000 |
| Metric | DSGX | CRL |
|---|---|---|
| Price | $85.69 | $217.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 14 |
| Target Price | $117.11 | ★ $193.17 |
| AVG Volume (30 Days) | 347.9K | ★ 633.2K |
| Earning Date | 12-03-2025 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.65 | N/A |
| EPS | ★ 1.78 | N/A |
| Revenue | $703,706,000.00 | ★ $4,023,704,000.00 |
| Revenue This Year | $12.36 | N/A |
| Revenue Next Year | $10.93 | $1.68 |
| P/E Ratio | $48.05 | ★ N/A |
| Revenue Growth | ★ 11.39 | N/A |
| 52 Week Low | $78.88 | $91.86 |
| 52 Week High | $124.31 | $216.76 |
| Indicator | DSGX | CRL |
|---|---|---|
| Relative Strength Index (RSI) | 43.32 | 76.74 |
| Support Level | $83.57 | $194.93 |
| Resistance Level | $88.22 | $205.00 |
| Average True Range (ATR) | 1.62 | 4.98 |
| MACD | -0.56 | 0.91 |
| Stochastic Oscillator | 30.66 | 93.19 |
Descartes Systems Group provides a software solution that allows users in the shipping industry to communicate with one another. Its core product is the Global Logistics Network, which is best understood as transaction-driven. Descartes charges clients to send/receive messages, data, and documents on the GLN. Customers typically contract for a monthly minimum over a multiyear period. The GLN platform allows Descartes to upsell additional software modules as well, typically provided via a software-as-a-service model.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.